Company news: Merck, Pfizer and Dendreon

Merck said Tuesday that it has agreed to acquire specialty pharmaceutical company Inspire for about $430 million. Inspire, which has its own US eye care sales force, develops and sells ophthalmic products and is co-developing glaucoma eye drop Saflutan with Merck. Beverly Lybrand, SVP and GM of neuroscience and ophthalmology at Merck, said in a statement that Inspire's commercial organization will strengthen Merck's ophthalmology business. In January, a cystic fibrosis drug that Inspire was developing, denufosol, failed in late-stage trials.

Pfizer reached a deal to sell its Capsugel manufacturing unit to KKR & Co. for $2.4 billion. The unit, which makes wholesale pill casings and had been acquired in Pfizer's 2000 purchase of Warner-Lambert, had $750 million in sales last year. Pfizer said it will use proceeds to buy back additional shares, and it lowered 2011 revenue expectations, to $65.2 billion to $67.2 billion, down from $66 billion to $68 billion. Pfizer, facing the loss of revenue from Lipitor when its patent expires later this year, could be looking to trim the revenue base to $35-40 billion by selling or spinning off additional business units, wrote Sanford C. Bernstein analyst Tim Anderson yesterday in an investor note: “To achieve this, Pfizer's nutritionals, consumer health, animal health, and Established Products drug division may be jettisoned.”

The Centers for Medicare & Medicaid Services (CMS) proposed covering the $93,000 cost of Dendreon's prostate cancer drug Provenge. A final decision is set for June 30 following a 60-day public comment period. The proposal means the government is likely to continue paying for on-label use of the drug in men with asymptomatic/minimally symptomatic castrate-resistant prostate cancer. With government reimbursement, analysts predict Provenge sales could reach $1 billion next year.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions